This is an automatically translated article.
DnaStomat drug has the main active ingredient Omeprazol in the form of pellets Omeprazol 8.5% with the content of 20mg. This is a medicine to treat specific gastrointestinal diseases such as treating stomach infections caused by HP bacteria, heartburn,...
1. What is DnaStomat?
What is DnaStomat drug? DnaStomat medicine has the main active ingredient Omeprazol in the form of pellets Omeprazol 8.5% with a strength of 20mg. This is a drug to treat specific gastrointestinal diseases such as treating stomach infections caused by HP bacteria, heartburn,...
DnaStomat drug is made in the form of hard capsules, suitable for oral use. drink directly.
Packing is a box of 10 blisters, each blister contains 10 pills or a box includes 1 vial, each bottle contains 14 pills.
1.1. Pharmacodynamics of the active ingredient Omeprazole Main active ingredient Omeprazole is a specific inhibitor that acts by blocking the enzyme system of Hydrogen-potassium Adenosine Triphosphatase, also known as the proton pump H + K + ATPase of gastric parietal cells.
1.2. Pharmacokinetics of the active ingredient Omeprazole Active ingredient Omeprazole is degraded in an acidic environment, so the drug is prepared in the form of a coated tablet that does not dissolve in the stomach, only absorbed in the duodenum and small intestine. The drug begins to act 1 hour after oral administration, peaks in plasma concentrations 2 hours after dosing, and complete absorption after 3 to 6 hours. Concomitant food absorption with Omeprazole has no effect on bioavailability. About 95% of omeprazole is bound to plasma proteins, mainly to albumin. The active substance Omeprazole is altered in the liver. Inactive plasma metabolites include sulfones, sulfides and hydroxy omeprazole. 80% of metabolites (hydroxy-ome-prazole and corresponding carboxylic acid) are excreted in the urine. The remaining 20% is excreted in feces. 1.3. The action of the active ingredient Omeprazole Active ingredient Omeprazole acts on the terminal stage of acid secretion, a single therapeutic dose of Omeprazole 20mg/day rapidly inhibits gastric secretion due to any stimulant. Omeprazole is a substance capable of inhibiting gastric acid secretion by blocking the proton pump of gastric parietal cells. Omeprazole has a strong and long-lasting effect. Therefore, this substance is used in the treatment of gastric ulcers - duodenal ulcers, Zollinger - Ellison syndrome, ... When using the active ingredient Omeprazol alone does not have the effect of killing HP bacteria, so it is necessary to use the active ingredient Omeprazol alone. combined with antibiotics to treat stomach ulcers caused by this bacteria.
2. What diseases does DnaStomat treat?
What disease does DnaStomat treat? DnaStomat is used in the treatment of the following diseases:
Treatment of stomach infections caused by H.P. Symptomatic treatment of people with frequent heartburn. Treatment of peptic ulcer. Treatment of gastroduodenal reflux disease. Treatment of severe peptic ulcers in Zollinger-Ellison syndrome.
3. Usage and dosage of DnaStomat
Usage and dosage of DnaStomat drug as follows:
3.1. Dosage of DnaStomat 3.1.1. Dosage for treatment of esophagus due to gastroesophageal reflux disease - oesophagitis Take DnaStomat for a period of 4 to 8 weeks, 1 time a day, 20-40mg each time. After a period of 4 to 8 weeks, take once a day, 20mg each time. 3.1.2. Dosage in Zollinger - Ellison syndrome Take 60mg once a day, can be taken twice a day for doses higher than 80mg, the dose should be under the guidance of the treating doctor and especially, do not stop using the drug at once. sudden way. 3.1.3. Dosage for treatment of gastric ulcers Take 20mg once in a day, the treatment dose can be doubled if the condition is severe (as directed by the treating doctor) and the duration of treatment is not more than 8 weeks. 3.1.4. Dosage for treatment of duodenal ulcer Take 20mg once in a day, the treatment dose can be doubled if the condition is severe (as directed by the treating doctor) and the duration of treatment does not exceed 4 weeks. 3.2 How to use DnaStomat Drug DnaStomat is made in the form of hard capsules, so you use the drug by taking it directly or taking it with a little water. DnaStomat should be swallowed whole and should not be crushed or chewed. DnaStomat should not be used for a long time (up to 4 weeks for duodenal ulcers and 8 weeks for gastric ulcers). To avoid recurrent ulcers and non-healing scars, H.P. must be completely eradicated and the non-steroidal anti-inflammatory drug dose should be discontinued or reduced. 3.3. How to handle missed dose, overdose of DnaStomat In case of missed dose: Take the missed dose of DnaStomat as soon as you remember. If the time to use DnaStomat is too close to the next day, skip the old dose and continue on the new day as scheduled. In case of overdose: There is very little information on DnaStomat overdose. When you have accidentally used an overdose of DnaStomat, it is necessary to conduct symptomatic treatment. Immediately contact the treating physician or take the person who overdosed to the nearest medical facility for appropriate treatment.
4. Undesirable effects of the drug DnaStomat
In the process of using DnaStomat you may experience some unwanted effects, including:
Common unwanted effects of DnaStomat, including:
Headache, drowsiness, dizziness. Nausea, vomiting, abdominal pain, diarrhea, constipation, abdominal distension. Uncommon side effects of DnaStomat, including:
Insomnia, confusion, dizziness with fatigue. Urticaria, itching, red rash on the skin. Increased transaminase index (reversible). Rare adverse effects of this drug include:
Sweating, peripheral edema, hypersensitivity reactions including angioedema, fever and anaphylactic reactions. Decrease in white blood cell count, decrease in platelet count, decrease in whole blood cells, agranulocytosis. Psychiatric disturbances such as reversible confusion, agitation, depression, hallucinations in elderly patients and especially in critically ill patients, hearing disturbances. Gynecomastia in men. Gastritis, Candida infection or dry mouth. Hepatitis with or without jaundice, encephalopathy in people with liver failure. Bronchospasm. Joint pain, muscle pain. Interstitial nephritis. In the process of using DnaStomat, if you experience unwanted effects, you need to actively notify the treating doctor for appropriate solutions.
5. Drug interactions DnaStomat
DnaStomat drug may interact with a number of drugs, specifically as follows:
Co-administration of DnaStomat with Ciclosporin: increases the blood concentration of Ciclosporin. Concomitant use of DnaStomat with drugs Diazepam, Phenytoin and drugs Warfarin: increases the concentration of these drugs in the blood. Taking DnaStomat with Dicoumarol: increases anticoagulant effect. The use of Nifedipine together with DnaStomat reduces the metabolism and increases the effect of Nifedipine. Clarithromycin used together with DnaStomat reduces the metabolism and doubles the concentration of Omeprazole. When using DnaStomat together with antibiotics that kill HP bacteria, the effect of these antibiotics is increased. To ensure effective medication use, you need to proactively make a list of all the medications you are taking and show it to your treating doctor for proper advice.
6. Some notes when using DnaStomat
During the use of DnaStomat, patients need to pay attention to the following:
6.1. Contraindications of DnaStomat Drug DnaStomat is contraindicated in people with known hypersensitivity or hypersensitivity to Omeprazol, Esomeprazole, or other Benzimidazole derivatives (such as Lansoprazole, Pantoprazol, Rabeprazol) or any of the ingredients. of drugs.
6.2. Note and caution when using DnaStomat If the person using DnaStomat has symptoms such as weight loss, prolonged vomiting, difficulty swallowing, vomiting blood or black stools), suspected or is having stomach ulcers. thickening, the possibility of malignancy should be excluded. This is because treatment can alleviate symptoms and delay diagnosis. Like other acid blockers, DnaStomat may decrease the absorption of vitamin B12 (cyanocobalamin) due to a decrease or lack of hydrochloric acid. Therefore, this factor should be considered for those with reduced body stores or at risk of reduced vitamin B12 absorption if treatment is prolonged. Omeprazole is an inhibitor of CYP2C19. When starting or ending treatment with the active ingredient omeprazole, the risk of drug interactions with drugs metabolised by CYP2C19 should be taken into account. When monitoring drug interactions between clopidogrel and DnaStomat, the clinical correlation of this interaction is not clear. However, as a precaution, clopidogrel and drugs containing the active ingredient omeprazole should not be used concurrently. Severe hypomagnesaemia has been reported in people treated with DnaStomat for at least 3 months and in most cases for about 1 year. Symptoms of severe hypomagnesaemia can occur such as fatigue, muscle spasms, delirium, convulsions, dizziness, and ventricular arrhythmias, but these signs may be insidious and go unnoticed. arrive. The treating physician may prescribe measurement of magnesium levels before starting treatment and periodically during treatment for those who need long-term treatment or must take DnaStomat concomitantly with digoxin or other drugs that cause depression. blood magnesium (specifically as diuretics). Use of DnaStomat, especially in high doses and for long periods of time (> 1 year), may slightly increase the risk of hip, wrist, and spine fractures, which mainly occur in the elderly or in the presence of other risk factors. Persons at risk of osteoporosis should be cared for according to currently available clinical guidelines and should be adequately supplemented with vitamin D and calcium. Absolutely do not drive or operate machinery while taking the drug because DnaStomat affects the nerves and reduces the alertness of the user. DnaStomat can mask the symptoms of malignancies, making it difficult to diagnose, so make sure the person taking DnaStomat doesn't have any malignancies before taking it. The pharmacokinetics of DnaStomat were not significantly altered in the elderly or in patients with impaired renal function. In subjects with impaired liver function, bioavailability of the drug is increased and clearance is reduced, but there is no accumulation of the drug and its metabolites in the body. 6.3. Note for pregnant and lactating women Effects of DnaStomat on pregnant women: Although in experimental studies, it was not found that the active ingredient Omeprazole has the potential to cause malformations and toxicity to the fetus, but not to the fetus. should be used for pregnant women, especially in the first 3 months of pregnancy. Lactation: The use of drugs containing the active ingredient Omeprazole, specifically DnaStomat, is not recommended in breast-feeding women. Above is all information about the drug DnaStomat, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy DnaStomat to treat the disease at home, because there may be unwanted side effects on health.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
